However, there is limited experience in patients with severe hepatic impairment, and the medication should be used cautiously in this population
The researchers determined that because the incidence rate was so low, GLP-1 use was not associated with a substantially increased risk of developing thyroid cancer, though they couldnt exclude a small increase in risk. The study also did a secondary analysis comparing 111,744 patients who took GLP-1 drugs to 149,179 patients who took another form of diabetes drug called SGLT2 inhibitors, and the results were consistent with the DPP4 inhibitor comparison
66 NBDHEX GST-inhibitory effects have also been observed in HL60 cells and their chemotherapy-resistant phenotype HL60/DNR
Clinical Safety & Considerations Before starting peptide therapy: Get Baseline Labs: IGF-1 Fasting glucose and insulin Lipid panel Thyroid and cortisol markers Monitor: Response to treatment Sleep quality and muscle recovery Adverse effects: water retention, joint pain, injection site irritation Contraindications: Active cancer Uncontrolled diabetes Pregnant or breastfeeding Prior history of pituitary disorders All peptides should be prescribed and monitored by a licensed medical provider using pharmaceutical-grade compounds
Mazdutide (IBI362, LY3305677, CAS 2259884-03-0) is a synthetic 39 amino acid long-acting oxyntomodulin analog and unimolecular dual agonist of GLP-1R and GCGR
